A system dynamics approach to pollution remediation and mitigation based on increasing the share of renewable resources.

This study explores the role of renewable energy (RE) penetration in Malaysia's energy security (ES) and its implications for the country's target of 20% capacity in the energy mix by 2025. Renewable energy (RE) is a critical driver of long-term energy security. In 2018, the share of renewable energy in Malaysia's energy mix was 9%, falling far short of the national target of 20% penetration by 2025. This study employs a system dynamics approach to investigate the relationship between RE penetration and correlated indicators from energy security (ES) dimensions: energy availability, environmental sustainability, and socio-economics. The causal relationships between the three-dimensional indicators of ES have been established using causal and stock and flow logic. Simulated results show that energy consumption has increased sharply, while energy efficiency and economic growth have only increased by a small margin with an increase in RE from 2015 to 2020. The energy intensity is expected to rise slightly by the end of the fifth year. As a result, the overall impact is positive for Malaysia's environmental sustainability while reducing its reliance on energy imports and meeting national economic growth demands.

Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride.

The pharmacokinetics, excretion, and metabolism of milnacipran were evaluated after oral administration of a 100-mg dose of [¹4C]milnacipran hydrochloride to healthy male subjects. The peak plasma concentration of unchanged milnacipran (∼240 ng/ml) was attained at 3.5 h and was lower than the peak plasma concentration of radioactivity (∼679 ng Eq of milnacipran/ml) observed at 4.3 h, indicating substantial metabolism of milnacipran upon oral administration. Milnacipran has two chiral centers and is a racemic mixture of cis isomers: d-milnacipran (1S, 2R) and l-milnacipran (1R, 2S). After oral administration, the radioactivity of almost the entire dose was excreted rapidly in urine (approximately 93% of the dose). Approximately 55% of the dose was excreted in urine as unchanged milnacipran, which contained a slightly higher proportion of d-milnacipran (∼31% of the dose). In addition to the excretion of milnacipran carbamoyl O-glucuronide metabolite in urine (∼19% of the dose), predominantly as the l-milnacipran carbamoyl O-glucuronide metabolite (∼17% of the dose), approximately 8% of the dose was excreted in urine as the N-desethyl milnacipran metabolite. No additional metabolites of significant quantity were excreted in urine. Similar plasma concentrations of milnacipran and the l-milnacipran carbamoyl O-glucuronide metabolite were observed after dosing, and the maximum plasma concentration of l-milnacipran carbamoyl O-glucuronide metabolite at 4 h after dosing was 234 ng Eq of milnacipran/ml. Lower plasma concentrations (<25 ng Eq of milnacipran/ml) of N-desethyl milnacipran and d-milnacipran carbamoyl O-glucuronide metabolites were observed.